Selegiline in Treatment of Cocaine Dependence - 2

This study has been completed.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
James Cornish, University of Pennsylvania
ClinicalTrials.gov Identifier:
NCT00000188
First received: September 20, 1999
Last updated: March 11, 2013
Last verified: March 2013
  Purpose

The purpose of this study is to assess selegiline as a pharmacotherapy for cocaine dependence.


Condition Intervention Phase
Cocaine-Related Disorders
Drug: Selegiline
Phase 2

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Selegiline in Treatment of Cocaine Dependence

Resource links provided by NLM:


Further study details as provided by University of Pennsylvania:

Primary Outcome Measures:
  • Retention
  • Cocaine use
  • Cocaine craving

Enrollment: 50
Study Start Date: September 1994
Study Completion Date: October 1995
Primary Completion Date: October 1995 (Final data collection date for primary outcome measure)
  Eligibility

Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Please contact site for information.

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00000188

Locations
United States, Pennsylvania
PDVAMC Treatment Research Center
Philadelphia, Pennsylvania, United States, 19104
Sponsors and Collaborators
University of Pennsylvania
Investigators
Principal Investigator: James Cornish, M.D. University of Pennsylvania
  More Information

No publications provided

Responsible Party: James Cornish, Principal Investigator, University of Pennsylvania
ClinicalTrials.gov Identifier: NCT00000188     History of Changes
Other Study ID Numbers: NIDA-00144-2, 3R01DA012268, K20-00144-2
Study First Received: September 20, 1999
Last Updated: March 11, 2013
Health Authority: United States: Federal Government

Additional relevant MeSH terms:
Cocaine-Related Disorders
Substance-Related Disorders
Mental Disorders
Selegiline
Monoamine Oxidase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Neuroprotective Agents
Protective Agents
Physiological Effects of Drugs
Central Nervous System Agents
Therapeutic Uses
Antiparkinson Agents
Anti-Dyskinesia Agents

ClinicalTrials.gov processed this record on July 23, 2014